Myelodysplastic Syndromes: all 2,165 studies

Page 8 of 22. Open to participants first (322), then studies with results posted, then the rest; newest registration first within each.

• Ondansetron Versus Aprepitant Plus Ondansetron for EmesisCompletedNCT00954941Phase 2Results posted
• Cyproheptadine Hydrochloride and Nutritional Supplementation in Treating Young Patients With Weight Loss With CancerTerminatedNCT00949117Phase 2Results posted
• Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)CompletedNCT00948064Phase 2Results posted
• A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML).CompletedNCT00946647Phase 1/2Results posted
• Combined Haploidentical-Cord Blood Transplantation for Adults and ChildrenCompletedNCT00943800Not applicableResults posted
• Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy StudyCompletedNCT00940602Phase 2Results posted
• Study of LBH589 for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)TerminatedNCT00939159Phase 2Results posted
• Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the BloodCompletedNCT00923910Phase 1/2Results posted
• Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHDTerminatedNCT00914940Phase 2Results posted
• A Pharmacokinetic And Pharmacodynamic Study Of Oral Lenalidomide (Revlimid) In Subjects With Low- Or Intermediate-1-Risk Myelodysplastic SyndromesCompletedNCT00910858Phase 1/2Results posted
• Decitabine and Clofarabine in Higher Risk Myelodysplastic Syndromes (MDS)CompletedNCT00903760Phase 2Results posted
• PR1 Vaccination in Myelodysplastic Syndrome (MDS)TerminatedNCT00893997Phase 2Results posted
• Controlled Study of Post-transplant Azacitidine for Prevention of Acute Myelogenous Leukemia and Myelodysplastic Syndrome Relapse (VZ-AML-PI-0129)CompletedNCT00887068Phase 3Results posted
• Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (H-R MDS)CompletedNCT00882102Phase 2Results posted
• Trial of High Dose Lenalidomide in Patients With MDS and AML With Trilineage DysplasiaTerminatedNCT00867308Phase 2Results posted
• Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic LeukemiaCompletedNCT00860574Phase 2Results posted
• Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure DisordersCompletedNCT00856388Not applicableResults posted
• Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and AnemiaActive, not recruitingNCT00843882Phase 3Results posted
• Efficacy and Safety of Lenalidomide in Combination With Cyclosporine A in Patients With Myelodysplastic SyndromesTerminatedNCT00840827Phase 2Results posted
• Clofarabine and Cytarabine in Treating Older Patients With AML or High-Risk MDSCompletedNCT00839982Phase 1/2Results posted
• Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML)CompletedNCT00831766Phase 1/2Results posted
• A Phase 2 Trial of MLN8237 in Adult Participants With Acute Myelogenous Leukemia and High-Grade Myelodysplastic SyndromeCompletedNCT00830518Phase 2Results posted
• Umbilical Cord Blood (UCB) Transplant, Fludarabine, Melphalan, and Anti-thymocyte Globulin (ATG) in Treating Patients With Hematologic CancerTerminatedNCT00827099Phase 2Results posted
• Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic CancerTerminatedNCT00818961Phase 2Results posted
• Bortezomib and Vorinostat in Treating Patients With High-Risk Myelodysplastic Syndrome or Acute Myeloid LeukemiaTerminatedNCT00818649Phase 2Results posted
• Study of CC-5013 to Evaluate Safety, Pharmacokinetics and Effectiveness for Japanese Patients With Symptomatic Anemia Associated With Myelodysplastic Syndrome With a Del(5)(q31-33) Abnormality.CompletedNCT00812968Phase 2Results posted
• Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCYCompletedNCT00809276Phase 1/2Results posted
• RAD001(Everolimus) in Treating Patients With Myelodysplastic SyndromesTerminatedNCT00809185Phase 2Results posted
• Thymoglobulin and Cyclosporine in Patients With Aplastic Anemia or Myelodysplastic SyndromeCompletedNCT00806598Phase 2Results posted
• Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematological Cancer Who Are Undergoing Umbilical Cord Blood TransplantCompletedNCT00796068Phase 2Results posted
• A Study of JNJ-30979754 (Decitabine) in Patients With Myelodysplastic SyndromeCompletedNCT00796003Phase 1Results posted
• Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell TransplantCompletedNCT00795769Phase 2Results posted
• Hematopoietic Cell Transplantation for Pediatric Patients With Hematologic MalignanciesCompletedNCT00795132Phase 2Results posted
• Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT00795002Phase 2Results posted
• Bendamustine in Acute Leukemia and MDSTerminatedNCT00790855Phase 1/2Results posted
• Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic CancerCompletedNCT00789776Phase 1/2Results posted
• Low Dose Melphalan and Bortezomib for AML and High-Risk MDSCompletedNCT00789256Not applicableResults posted
• Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological CancerCompletedNCT00787761Phase 2Results posted
• Combination Chemotherapy, Donor Stem Cell Transplant, Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide in Treating Patients With Hematologic CancerCompletedNCT00782379Phase 2Results posted
• Clofarabine Plus Low-Dose Cytarabine Induction and Decitabine Consolidation in Frontline Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)CompletedNCT00778375Phase 2Results posted
• High-dose Cytarabine/Mitoxantrone Followed by Autotransplantation for t-MDS/t-AMLCompletedNCT00774046Phase 2Results posted
• Trial of Decitabine in Patients With Acute Myelogenous Leukemia or Myelodysplastic SyndromeCompletedNCT00760084Phase 2Results posted
• Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure DisorderCompletedNCT00755040Phase 3Results posted
• An Efficacy and Safety Study of Decitabine in Participants With Myelodysplastic Syndrome (MDS)CompletedNCT00744757Phase 2Results posted
• Decitabine, Cytarabine, GCSF for Refractory AML/MDSTerminatedNCT00740181Phase 2Results posted
• Conditioning Regimen and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematologic Malignancies.CompletedNCT00739141Phase 2Results posted
• Methadone, Morphine, or Oxycodone in Treating Pain in Patients With CancerTerminatedNCT00726830Not applicableResults posted
• Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic CancerCompletedNCT00723099Phase 2Results posted
• 5-Azacytidine Prior to Allogeneic Stem Cell Transplant in High Risk Myelodysplastic SyndromeCompletedNCT00721214Phase 2Results posted
• Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic DiseaseCompletedNCT00719888Phase 2Results posted
• Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematological Cancer or Other DiseaseTerminatedNCT00719849Phase 2Results posted
• American Ginseng in Treating Patients With Fatigue Caused by CancerCompletedNCT00719563Phase 3Results posted
• Reduced Intensity Total Body Irradiation + Thymoglobulin Followed by Allogeneic PBSCTCompletedNCT00709592Phase 2Results posted
• Low-dose Oral Clofarabine for the Treatment of IPSS INT-1, INT-2 or HIGH Myelodysplastic Syndromes and Chronic Myelomonocytic LeukemiaTerminatedNCT00708721Phase 1/2Results posted
• Clofarabine for Myelodysplastic Syndrome (MDS) Patients Who Failed Vidaza Treatment (tx)TerminatedNCT00700011Phase 2Results posted
• A Dose Range Finding Study of Lenalidomide in Non-5q Chromosome Deletion in Low and Intermediate Risk Myelodysplastic Syndrome (MDS) PatientsTerminatedNCT00699842Phase 1/2Results posted
• A Study Evaluating Epoetin Alfa 40,000 IU (International Units) Every Week or 80,000 IU Every Week Compared to Placebo in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes at Risk for TransfusionTerminatedNCT00695396Phase 3Results posted
• LBH589 Plus Decitabine for Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML)CompletedNCT00691938Phase 1/2Results posted
• Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell TransplantCompletedNCT00691015Phase 2Results posted
• Study of Temozolomide in Previously Untreated Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Participants With Low O6-Methylguanine Methyltransferase (MGMT) Expression (P05052)CompletedNCT00687323Phase 2Results posted
• T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic MalignanciesCompletedNCT00683046Phase 2Results posted
• INCB018424 in Patients With Advanced Hematologic MalignanciesCompletedNCT00674479Phase 2Results posted
• Unrelated Cord Blood Transplant Plus a Haplo-Identical (Half-Matched), T-Cell Depleted Stem Transplant From a Related Donor for Subjects With High Risk MalignanciesCompletedNCT00673114Phase 1/2Results posted
• Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer PainCompletedNCT00666211Phase 3Results posted
• Pre-Transplant 5-Azacitidine In Patients With High-Risk Myelodysplastic Syndrome Who Are Candidates For Allogeneic Hematopoietic Cell TransplantCompletedNCT00660400Not applicableResults posted
• Deferoxamine for Iron Overload Before Allogeneic Stem Cell TransplantationTerminatedNCT00658411Not applicableResults posted
• Phase II Study of Idarubicin, Cytarabine, and Vorinostat With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)CompletedNCT00656617Phase 2Results posted
• A Randomized Trial of Procrit vs. No Procrit in AML and High Risk MDSCompletedNCT00656448Phase 3Results posted
• Rituximab (Rituxan) for the Prevention of EBV-LPD Epstein Barr Virus (EBV) Lymphoproliferative Disorder Post T Cell Depleted Unrelated and HLA Mis-matched Related HSCTCompletedNCT00648037Not applicableResults posted
• Busulfan, Melphalan, and Fludarabine With Peri-transplant Palifermin, Followed by a T-Cell Depleted Hematopoietic Stem Cell Transplant From HLA Matched or Mismatched Related or Unrelated Donors in Patients With Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)CompletedNCT00629798Phase 2Results posted
• Clofarabine and Non-Myeloablative Allogeneic Hematopoietic TransplantationTerminatedNCT00626626Phase 1/2Results posted
• Study of Oral Dasatinib in Subjects With Myelodysplastic Syndrome (MDS) and Excess Marrow BlastsCompletedNCT00624585Not applicableResults posted
• Cephalon Decitabine, Arsenic Trioxide and Ascorbic Acid for Myelodysplastic SyndromeCompletedNCT00621023Phase 2Results posted
• Donor Peripheral Stem Cell Transplant, Fludarabine, and Busulfan in Treating Patients With Hematologic CancersCompletedNCT00619645Phase 2Results posted
• A Study of Decitabine Given Subcutaneously to Adults With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)CompletedNCT00619099Phase 2Results posted
• Romiplostim Treatment of Thrombocytopenia in Subjects With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)CompletedNCT00614523Phase 2Results posted
• Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic CancerCompletedNCT00611351Phase 2Results posted
• Treatment of Single or Double Umbilical Cord Trans + Graft-versus-host Disease (GVHD) Prophylaxis w/ Tacrolimus & Mycophenolate MofetilTerminatedNCT00608517Not applicableResults posted
• Study of Voreloxin (Vosaroxin) in Older Patients With Untreated Acute Myeloid LeukemiaCompletedNCT00607997Phase 2Results posted
• Stem Cell Transplant Using Peripheral and Cord Blood Stem Cells to Treat Severe Aplastic Anemia and Myelodysplastic SyndromeCompletedNCT00604201Phase 2Results posted
• Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed, Previously Untreated Acute Myeloid LeukemiaCompletedNCT00602771Phase 2Results posted
• Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell TransplantTerminatedNCT00602446Phase 2Results posted
• Efficacy Study of T Cell Depleted Allogeneic Non-myeloablative Stem Cell TransplantCompletedNCT00597714Phase 2Results posted
• A Myeloablative Conditioning Regimen and Total Body Irradiation Followed by the Transplantation for Patients With Hematological MalignancyCompletedNCT00597519Phase 2Results posted
• LBH589 in Refractory Myelodysplastic Syndromes (MDS)TerminatedNCT00594230Phase 2Results posted
• Clofarabine, Cytarabine, and Thymoglobulin for Allogeneic TransplantationTerminatedNCT00593645Phase 2Results posted
• T-Cell Depletion, Donor Hematopoietic Stem Cell Transplant (HSCT), and T-Cell Infusions in Treating Patients With Hematologic Cancer or Other DiseasesTerminatedNCT00589602Phase 2Results posted
• Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological CancerCompletedNCT00589563Phase 2Results posted
• Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation and Donor Bone Marrow Transplant in Treating Patients With Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or High-Risk Myelodysplastic SyndromeTerminatedNCT00589316Phase 1Results posted
• Selumetinib in Treating Patients With Recurrent or Refractory Acute Myeloid LeukemiaCompletedNCT00588809Phase 2Results posted
• Trial of Allogeneic Stem Cell Transplants From HLA Compatible, Related and Unrelated Donors After a Myeloablative Preparative Regimen With Hyperfractionated TBI, Thiotepa and Fludarabine For Adult Patients With Lymphohematopoietic DisordersCompletedNCT00587054Phase 2Results posted
• Phase II Trial of a Chemotherapy Alone Regimen of IV Busulfan (Busulfex), Melphalan and Fludarabine as Myeloablative Regimen Followed by an Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplant From an HLA-Identical, or HLA-Non Identical Related or Unrelated DonorCompletedNCT00582933Phase 2Results posted
• Allo Non-Myeloablative SCT Utilizing Mis-Matched Family Member Stem Cells Purged Using CampathCompletedNCT00580034Phase 2Results posted
• Allo Non-myeloablative SCT Utilizing Matched Family Member Stem Cells Purged Using CampathCompletedNCT00578942Phase 2Results posted
• Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell TransplantCompletedNCT00571662Phase 2Results posted
• Phase I/II Study of 5-Azacytidine With Ara-C in Patients With Relapsed/Refractory Acute Myelogenous Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)CompletedNCT00569010Phase 1/2Results posted
• Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological MalignanciesCompletedNCT00566696Phase 2Results posted
• Study of Stem Cell Transplantation for Hematologic Malignancies Using Clofarabine and Busulfan RegimenCompletedNCT00556452Phase 1/2Results posted
• Alemtuzumab, Busulfan, and Cyclophosphamide Followed By a Donor Stem Cell Transplant in Treating Patients With Hematologic CancerTerminatedNCT00555048Phase 1/2Results posted
• A Study of NeoRecormon (Epoetin Beta), CellCept (Mycophenolate Mofetil) and Prednisone in Patients With Low or Intermediate Myelodysplastic Syndromes.CompletedNCT00551291Phase 2Results posted

← Myelodysplastic Syndromes overview